AI assistant
Xvivo Perfusion — Board/Management Information 2017
Jul 17, 2017
3130_rns_2017-07-17_eb2fb69e-b6e1-420a-8f13-8fe973a4f722.pdf
Board/Management Information
Open in viewerOpens in your device viewer
Press release July 17, 2017 Gothenburg
XVIVO Perfusion´s CFO appointed Deputy CEO
XVIVO Perfusion's CFO Christoffer Rosenblad has been appointed Deputy CEO with effect from July 17, 2017. Christoffer has been employed as CFO in the company since 2012 and will continue to be the company's CFO.
July 17, 2017 Gothenburg Magnus Nilsson, CEO XVIVO Perfusion AB (publ)
For further information please contact: Magnus Nilsson, CEO, tel +46 31 788 2150, email: [email protected]
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in the USA. The Xvivo share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.
_____________________________________________________________________________________________________
_____________________________________________________________________________________________________
XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424. Tel: +46 31 788 21 50. Fax: +46 31 788 21 69. E-mail: [email protected]. Website: www.xvivoperfusion.com
The information was submitted for publication, through the agency of the contact person set out above, at 8:30 a.m. CET on July 17, 2017.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.